
    
      (ARDS caused by Non-COVID-19 cohort): The objectives of this clinical study is to investigate
      the efficacy and safety of NOA-001 in patients with ARDS caused by Non-COVID-19. The number
      of patients enrolled is 30 (20 patients in the NOA-001 group and 10 patients in the standard
      therapy group).

      (ARDS caused by COVID-19 cohort): The objectives of this clinical study is to investigate the
      efficacy and the safety of NOA-001 in patients with ARDS caused by COVID-19. The number of
      patients enrolled is 5 (in the NOA-001 group only).
    
  